NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
- NHS England
Procurement identifier (OCID): ocds-h6vhtk-04e273
Description
NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/>CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/>CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026
Notices
F03: Contract award notice
- Notice identifier
- 2025/S 000-043951
- Published
- 29 July 2025, 3:34pm
F02: Contract notice
- Notice identifier
- 2025/S 000-005287
- Published
- 17 February 2025, 9:56am